Zimmer Biomet Holdings Inc (ZBH): analysis and signal as of September 3, 2026
In short
The system issues no signal on Zimmer Biomet Holdings as of 2026-09-03, with a vote of 3/3 and a score of -1,00. The US estate tax penalty, which drives the deterministic score, outweighs the stock's discounted valuation.
- Current signal
- no signal (vote 3/3)
- Deterministic score
- -1.0 → signal expected by the scale : weak (September 10, 2026)
- Layers
- fundamentals : positive, price : positive, risks : positive
Triggered rules
| Rule | Weight |
|---|---|
| penalizes direct holding of US securities in a CTO (US estate tax at death), favors a UCITS ETF domiciled in IE | -1.0 |
Thesis
The discounted valuation, with a forward PER of 11,35 against 18 to 25 for medtech peers, gives this defensive healthcare player a structural appeal. Persistent margin compression, shown by net income down 2,0 % over one year despite revenue up 8,6 %, reflects the integration costs of Salesforce and of external growth. It tempers the potential for a re-rating of the multiples in the short term. The negative deterministic score of -1,00, tied to the fis-estate-tax-us rule, maintains the absence of signal at a price of 99,50 USD.
Bull case
Zimmer Biomet combines several strengths. The defensive healthcare sector is explicitly favored by the EXPANSION macroeconomic regime, which shows a bullish bias of 0,58. The valuation remains attractive relative to medtech peers, with a 30 to 50 % discount on the PER. Volatility stays low, with a beta of 0,47. The stock also brings a diversification contribution, with variance reduced by 6,0 % under the Choueifaty-Coignard 2008 method.
Bear case
The deterministic score of -1,00 reflects the US estate tax penalty and blocks any signal. Margin compression is settling in over time. The stock has accumulated two years of value destruction from opening price gaps, for a total of -22,8 %. Elective procedures remain sensitive to economic cycles. The MDL litigation on metal-on-metal implants inherited from Biomet constitutes a persistent legal risk. These obstacles limit a rapid re-rating before the T3 results of early November 2026.
Scenarios
The bullish scenario, with a 30 % probability, rests on solid T3 results and a re-rating toward a PER of 13 to 14 times. The central scenario, with a 50 % probability, describes a sideways move in the price under the effect of persistent margin compression. The bearish scenario, with a 20 % probability, contemplates a maximum decline of 20 % in case of worse margins, an adverse CMS decision or a relapse of the metal-on-metal litigation.
Risks
Invalidation of the thesis is assessed in a qualitative manner. A close below the 50-session moving average, together with a break in the flow structure, would call the reading of the stock into question. The main risks remain durable margin compression, the US estate tax penalty behind the score of -1,00, the sensitivity of elective procedures to the economic cycle, a possible relapse of the metal-on-metal litigation and a potential adverse CMS decision.
Market positioning (short sellers)
- Short interest / shares outstanding
- 4.63 %
- Days to cover
- 2.93
- Settlement date
- 2026-08-14
- Source
- FINRA (disseminated on 2026-08-26)
Upcoming catalysts
| Date | Description |
|---|---|
| T3 2026 Results and FY26 margin guidance | |
| Stifel Healthcare Conference |
Signal history (last 12 months)
| Date | Signal | New fact |
|---|---|---|
| no signal (3/3) | Unchanged. No new dated quantitative data since the verdict of 2026-09-01. The price of 99,50 USD on 2026-09-02 remains consistent with the current reading, with no results, no revision of forecasts and no recent regulatory or litigation news. The mention of a possible stale character of the analysis layers does not count as a new fact. The deterministic score remains at -1,00 on the same fis-estate-tax-us rule. | |
| no signal (single draw, outside the three-draw protocol) | unchanged |
Frequently asked questions
Why does the system issue no signal on this stock?
The deterministic score of -1,00, attached to the fis-estate-tax-us rule covering the US estate tax penalty, blocks the signal despite the 3/3 vote. This penalty outweighs the strengths of the stock, notably the valuation discount and the defensive profile. The EXPANSION macroeconomic regime, favorable to the healthcare sector, is not enough to reverse this verdict.
In what way does the valuation appear attractive?
The stock shows a forward PER of 11,35, against 18 to 25 for medtech peers, which is a discount of 30 to 50 %. This discount is observed on a defensive healthcare player, with a beta of 0,47 reflecting low volatility. A re-rating toward a PER of 13 to 14 times is the lever of the bullish scenario.
Which factors weigh on profitability?
Net income falls 2,0 % over one year while revenue grows 8,6 %. This margin compression reflects the integration costs of Salesforce and of external growth. It persists and limits the potential for a re-rating of the multiples in the short term, until the T3 results scheduled for early November 2026.
What are the main risks identified?
Four risks stand out. Durable margin compression penalizes profitability despite revenue growth. Elective procedures remain sensitive to economic cycles. The MDL litigation on metal-on-metal implants inherited from Biomet exposes the company to a legal relapse. Finally, two years of opening gaps have destroyed 22,8 % of value, and an adverse CMS decision would freeze the bearish scenario.
Has the situation changed since the last verdict?
No. No dated quantitative data has appeared since the verdict of 2026-09-01. The price of 99,50 USD recorded on 2026-09-02 remains consistent, with no results, no revision of forecasts and no recent regulatory or litigation news. The mention of a possible stale character of the analysis layers does not constitute a new fact. The deterministic score remains at -1,00 on the same rule.
Sources
The official filings below are the issuer's own, matched to this stock by its identifier (LEI, CIK or ISIN). The figures quoted above come from an automated arbitration: they have not been re-checked one by one.
- — 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; 7.01 Reg… (SEC · 8-K)
- — 8.01 Other Events; 9.01 Financial Statements and Exhibits (SEC · 8-K)
- — 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits (SEC · 8-K)
- — 10-Q (SEC · 10-Q)
Automated AI analysis: limitations and transparency
- This content is an automated analysis produced using artificial intelligence. Personal analysis for information purposes — no personalised investment advice. MMR content consists of general research. It does not take account of your financial circumstances, objectives or risk tolerance. Data, analyses and results, including those produced using artificial intelligence, may contain errors, be incomplete or become outdated. No return or outcome is guaranteed. All investments carry a risk of partial or total loss of capital. Past performance and simulations do not predict future results. Before making any decision, check information against original sources and, where necessary, consult an authorised professional. You remain responsible for your investment decisions. This notice does not exclude or limit any liability that cannot legally be excluded or limited.
- Tool and analysis: QDNA, Aurélien Ambert.
- Analysis (arbitration) completed on September 3, 2026; this page was completed on September 3, 2026 at 21:56 (UTC).
- Interests: no position in the stock analysed (ZBH) is recorded in the data consulted on (UTC). This does not confirm the absence of holdings or other interests. The situation at the analysis publication date has not been reconstructed.
- This declaration covers only recorded positions in this stock; it is not an exhaustive verification of other interests or remuneration.
- Methodology: analysis chain, score formula and scale described on the public methodology page.
- Analysis horizon: 2035.
See also
- Neighbouring stock in the same sector: AbbVie, Inc. (ABBV)
- All analysed stocks
- Public methodology